Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Ka/b/δ and anti-PD-1 treatment
This study shows that intermittent anti-PI3K treatment can overcome immune checkpoint therapy resistance in Pten-null prostate cancer by converting 'cold' tumors into T cell-inflamed ones.